← Eichor
Condition: Pdac Pancreatic Ductal Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Pdac Pancreatic Ductal Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06921928A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 · 34 location(s) · Incyte Corporation · NCT06179160Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarc
Phase N/A · 12 location(s) · Medical University of Graz · NCT05526443NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3 · 15 location(s) · SOFIE · NCT07217717A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)
Phase 2 · 13 location(s) · Belgian Group of Digestive Oncology · NCT05472259A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve
NA · 1 location(s) · Mayo Clinic · NCT07324096Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
Phase 2 · 6 location(s) · Sir Run Run Shaw Hospital · NCT06825546AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 · 3 location(s) · Avacta Life Sciences Ltd · NCT07454642PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
Phase N/A · 1 location(s) · University of Ulm · NCT04099134Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures
NA · 7 location(s) · Institut Curie · NCT05475366A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07124611Autologous CAR-T Cells Targeting B7-H3 in PDAC
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06158139Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring
Phase N/A · 1 location(s) · The Third Xiangya Hospital of Central South University · NCT06655233Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Phase 2 · 19 location(s) · Verastem, Inc. · NCT07644559AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Phase N/A · 3 location(s) · Changhai Hospital · NCT06638866Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
NA · 2 location(s) · Rutgers, The State University of New Jersey · NCT05296421Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT07214298PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pa
NA · 16 location(s) · Lipidica, a.s. · NCT06549725PRetreatment MRI for OCcult Liver Metastasis Assessment In Pancreatic Ductal adenocarcinoMa
Phase N/A · 1 location(s) · Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di · NCT07252076Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
NA · 1 location(s) · Minia University · NCT07148830Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Pancreatic Cancer Early Detection Consortium
Phase N/A · 60 location(s) · Arbor Research Collaborative for Health · NCT04970056M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid
Phase 1 · 5 location(s) · EMD Serono Research & Development Institute, Inc. · NCT07166601A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chem
Phase 2 · 24 location(s) · BioNTech SE · NCT07255404
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.